Literature DB >> 26525698

Prenatal predictors in postpartum recovery for acute fatty liver of pregnancy: experiences at a tertiary referral center.

Jinlai Meng1, Shan Wang1, Yongzhong Gu1, Hong Lv1, Jinjiao Jiang2, Xietong Wang3.   

Abstract

PURPOSE: The purpose of this study was to describe some prenatal characteristics and laboratory findings of acute fatty liver of pregnancy (AFLP) and provide the clinicians with reasonable predictors and expectation in postpartum recovery.
METHODS: At a tertiary referral center 43 patients with AFLP were entered into this retrospective study in 5 years based on the Swansea criteria. Emergent cesarean sections were performed within 24 h, and the criteria of recovery after operation was based on a uniform standard. All of them were hospitalized and treated at the same department of obstetrics and maternal intensive care unit.
RESULTS: Prenatally, all women with AFLP had elevated serum hepatic aminotransferase and serum bilirubin levels. Albumin level was decreased in 88 % women and hypoglycemia was documented in 56 % women. Plasma fibrinogen level of 93 % patients was less than 1.75 g/L and prothrombin time (PT) of 91 % was prolonged abnormally. The duration of recovery after delivery ranged from 5 to 20 days. Pearson correlation coefficient between duration of recovery and hyperbilirubinemia was 0.639 (P = 0.001). The levels of PT, plasma fibrinogen and platelet counts were also correlated with the recovery time (R = 0.459, P = 0.002; R = 0.427, P = 0.004; R = 0.435, P = 0.004). Elevated leukocytes, hypoglycaemia, hepatic aminotransferase and uric acid levels showed no value for predicting the prognosis of AFLP (P > 0.01).
CONCLUSIONS: AFLP is a rare but serious complication in the third trimester. Prenatal serum bilirubin, PT, plasma fibrinogen levels and platelet counts are the predictors of postpartum recovery, but some Swansea diagnosis criteria do not have the same prognostic significance as others.

Entities:  

Keywords:  Acute fatty liver of pregnancy; Outcome; Prognostic predictors

Mesh:

Substances:

Year:  2015        PMID: 26525698     DOI: 10.1007/s00404-015-3941-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Outcomes and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.

Authors:  Qiang Gao; Xin Qu; Xiukai Chen; Jicheng Zhang; Fen Liu; Suochen Tian; Chunting Wang
Journal:  Singapore Med J       Date:  2018-01-03       Impact factor: 1.858

Review 2.  Acute Fatty Liver Disease of Pregnancy: Updates in Pathogenesis, Diagnosis, and Management.

Authors:  Joy Liu; Tara T Ghaziani; Jacqueline L Wolf
Journal:  Am J Gastroenterol       Date:  2017-03-14       Impact factor: 10.864

3.  Acute Fatty Liver of Pregnancy: A Life-Threatening Condition Requiring a Life-Saving Approach.

Authors:  Mansoureh Gorginzadeh; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-05-25       Impact factor: 0.660

4.  HELLP Syndrome or Acute Fatty Liver of Pregnancy: A Differential Diagnostic Challenge: Common Features and Differences.

Authors:  Werner Rath; Panagiotis Tsikouras; Patrick Stelzl
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-05-18       Impact factor: 2.915

5.  Pregnancy outcomes of patients with acute fatty liver of pregnancy: a case control study.

Authors:  Lingzhi Chang; Ming Wang; Haixia Liu; Qinghua Meng; Hongwei Yu; Yu-Mei Wu; Yunxia Zhu
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-11       Impact factor: 3.007

6.  Early diagnostic test for acute fatty liver of pregnancy: a retrospective case control study.

Authors:  Yan Zhong; Fufan Zhu; Yiling Ding
Journal:  BMC Pregnancy Childbirth       Date:  2020-03-14       Impact factor: 3.007

7.  Potential predictors for prognosis and postpartum recovery time of acute fatty liver of pregnancy.

Authors:  Jun Chen; Ze-Bing Huang; Xue-Gong Fan; Xing-Wang Hu; Min Qi; Cheng-Jin Liao; Li-Yuan Long; Yan Huang
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-07       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.